pandion
therapeutics
highlights
potential
modular
biologics
pipeline
treatment
autoimmune
diseases
focis
watertown
globe
newswire
pandion
therapeutics
nasdaq
pand
biotechnology
company
developing
novel
therapeutics
designed
address
unmet
needs
patients
living
autoimmune
diseases
today
announced
presentation
preclinical
data
highlighting
potential
modular
biologics
pipeline
treatment
autoimmune
diseases
federation
clinical
immunology
societies
focis
virtual
annual
meeting
pandion
utilizes
talon
therapeutic
autoimmune
regulatory
protein
drug
design
discovery
platform
create
candidates
target
known
control
nodes
immune
system
drug
candidates
modularly
engineered
either
work
systemically
targeted
specific
tissues
via
tethering
modules
potentially
enabling
precision
medicine
approach
treating
autoimmune
diseases
posters
presented
focis
showed
vivo
proof
concept
immune
effectors
potential
broad
biological
effects
agonism
well
introduction
pandion
emerging
kidney
research
program
recent
evolution
understanding
immune
system
allowed
team
approach
treatment
autoimmune
diseases
fundamentally
new
way
activate
regulation
immune
response
rather
shutting
completely
believe
understanding
could
result
ability
develop
differentiated
therapies
living
autoimmune
diseases
said
jo
viney
chief
scientific
officer
pandion
therapeutics
data
presented
focis
underscore
enthusiasm
approach
demonstrating
localized
regulation
autoimmunity
animal
models
graft
versus
host
disease
focis
poster
presentations
available
pandion
website
https
key
findings
presented
focis
title
agonist
inhibits
cell
activation
ameliorates
intestinal
inflammation
authors
edwards
larkin
alioto
cluckey
rios
lurier
halvey
viney
otipoby
background
critical
immune
regulator
found
activated
conventional
cells
inhibition
treatment
cancer
result
autoimmune
diseases
including
colitis
contrast
activating
agonizing
results
attenuation
overactive
cells
providing
new
potential
treatment
approach
autoimmune
diseases
pandion
created
agonist
tethered
molecule
madcam
findings
demonstrated
tethered
agonism
without
blocking
normal
receptor
ligand
interaction
either
madcam
animal
model
graft
versus
host
disease
treatment
resulted
prolonged
survival
beyond
dosing
period
animal
model
graft
versus
host
disease
treatment
reduced
conventional
cell
infiltration
colon
demonstrating
localized
effect
tethered
molecule
title
localized
immunomodulation
cells
treatment
autoimmune
inflammatory
skin
diseases
authors
mande
rios
borthakur
boisvert
rowe
halvey
viney
mascanfroni
otipoby
background
pathogenic
cells
found
majority
chronic
skin
diseases
pandion
created
agonists
including
version
designed
regulate
attenuate
activity
pathogenic
cells
addition
pandion
created
effector
modules
designed
convert
proinflammatory
environment
environment
pandion
currently
evaluating
candidates
various
models
skin
autoimmune
diseases
findings
effectors
localized
skin
animal
model
vitiligo
agonist
reduced
skin
depigmentation
reduced
conventional
cells
systemic
effects
cells
animal
model
contact
hypersensitivity
significantly
inhibited
ear
inflammation
observed
effects
showing
localized
effect
tethered
molecules
title
generation
mutein
prevention
graft
rejection
renal
transplantation
authors
li
larkin
kiprono
rowe
visweswaraiah
willardsen
allen
otipoby
viney
shaheen
background
kidney
transplant
procedure
many
people
renal
disease
current
treatments
prevent
rejection
donor
kidney
serious
side
effects
findings
pandion
created
mutein
selectively
binds
kidney
tubular
epithelium
vivo
work
ongoing
understand
potential
tethered
molecule
expand
regulatory
cells
kidney
approach
treatment
kidney
inflammation
title
molecular
profiling
reveals
agonist
changes
key
immune
pathways
authors
halvey
lurier
cianci
viney
otipoby
background
critical
immune
regulator
found
activated
conventional
cells
inhibition
treatment
cancer
result
autoimmune
diseases
including
colitis
activating
agonizing
results
inhibition
conventional
cells
affords
potential
treatment
approach
autoimmune
diseases
pandion
created
agonist
systemic
agonist
agonism
promising
treatment
approach
autoimmune
diseases
findings
assays
agonism
resulted
suppression
many
known
immune
activation
pathways
including
differentiation
chemokine
signalling
pandion
therapeutics
pandion
therapeutics
developing
novel
therapeutics
designed
address
unmet
needs
patients
living
autoimmune
diseases
pandion
talon
therapeutic
autoimmune
regulatory
protein
drug
design
discovery
platform
enables
company
create
pipeline
product
candidates
using
immunomodulatory
effector
modules
ability
also
combine
effector
module
tether
module
bifunctional
format
pandion
lead
product
candidate
combination
mutein
effector
module
protein
backbone
designed
selectively
expand
regulatory
cells
systemically
without
activating
proinflammatory
cells
conventional
cells
natural
killer
cells
currently
phase
clinical
trial
pandion
continuing
develop
expand
library
effector
tether
modules
part
research
discovery
pipeline
information
please
visit
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
involve
substantial
risks
uncertainties
statements
statements
historical
facts
contained
press
release
including
statements
regarding
company
strategy
clinical
development
plans
timelines
prospects
statements
words
anticipate
believe
continue
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
based
management
current
expectations
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
risks
associated
pandion
ability
obtain
maintain
necessary
approvals
fda
regulatory
authorities
initiate
preclinical
studies
clinical
trials
product
candidates
advance
product
candidates
preclinical
research
clinical
trials
replicate
clinical
trials
positive
results
found
preclinical
studies
advance
development
product
candidates
timelines
anticipates
current
future
clinical
trials
obtain
maintain
protect
intellectual
property
rights
related
product
candidates
manage
expenses
raise
substantial
additional
capital
needed
achieve
business
objectives
discussion
risks
uncertainties
important
factors
could
cause
company
actual
results
differ
contained
statements
see
risk
factors
section
well
discussions
potential
risks
uncertainties
important
factors
company
recent
filings
securities
exchange
commission
addition
statements
included
press
release
represent
company
views
date
hereof
relied
upon
representing
company
views
date
subsequent
date
hereof
company
anticipates
subsequent
events
developments
cause
company
views
change
however
company
may
elect
update
statements
point
future
company
specifically
disclaims
obligation
contacts
media
kathryn
morris
yates
network
kathryn
investors
michelle
avery
pandion
therapeutics
investors
